Search PubMed⌕ Search

Biomedical subjects

M V Merrick

Publications and source records attributed to M V Merrick.

At least 109 records · Page 6Linked to original sources
PubMed1975

Indium (111In)-labelled bleomycin for the detection of intracranial lesions.

Brain scans with 99mTc pertechnetate were compared with scans made after administration of 111Indium bleomycin in 38 patients scanned on 41 occasions. They gave similar results in 34 pairs of examinations, including cases in which both failed to detect the tumour. In seven cases, the two agents differed. In two of these bleomycin distinguished residual tumour from the effects of craniotomy more clearly than did pertechnetate; in three bleomycin apparently detected tumour not seen with pertechnetate, and in two the differences may have been due to technical factors, or are unexplained.

Adult↗
PubMed1975

Serial Fluorine-18 bone scans in the follow-up of carcinoma of the prostate.

74 patients with prostatic cancer were studied annually by combined radiological and fluorine-18 scan survey over a 5-year period. The results of the long term follow-up of bone cans is reported. At the time of the initial diagnosis 71-5% of the patients had advanced disease and 56% had radiological or scan evidence of metastases. A critical evaluation of the scans resulted in the detection of early bone lesions in 25% of patients with no radiological evidence of metastases. Follow-up of these patients has shown that scan abnormalities preceded radiological changes from between 1 to 4 years and there was good correlation proven histologically by bone biopsy or autopsy in more than half of the patients. In patients with a positive bone scan and positive X-rays the scan abnormalities were more extensive than the corresponding X-ray lesions. When bone healing occurred with endocrine treatment this was more readily apparent on the X-rays. False negative scans were not seen with fluorine-18 which allows for greater accuracy in the detection of skeletal metastases. Bone scanning has enabled correct staging to be carried out. This study confirms the high incidence of cardiac and vascular complications in patients treated with oestrogens.

Aged↗
PubMed1975

The distribution and dosimetry of 111-IN-bleomycin in man.

The distribution of 111-In in the human body was studied after the injection of -111-In-bleomycin for tumour localization. Uptake in body organs was measured by quantitative scanning using a dual detector scanner. The estimated absorbed dose from an injection of 1 mCi was 0.3 rad to the whole body, and approximately 1 rad to bone marrow, kidneys, liver and spleen.

Bleomycin↗
PubMed1975

111-In-labelled bleomycin; clinical experience as a diagnostic agent in tumours of the thorax and abdomen.

The potential value of indium-labelled bleomycin as a diagnostic scanning agent has been investigated in patients with a variety of malignant neoplasms involving the thorax, abdomen or pelvis. Sixty-five patients were scanned on 72 occasions, the optimum time to perform the examination being 72 hours after the intravenous injection of 2 mCi 111-In chelated to 2 mg bleomycin. Tumour uptake was visualized in 53 out of 62 scans in which tumour was present, but the extent of tumour was underestimated in seven cases, and over-estimated in five others. The latter were mostly due to uptake in infective lesions. These results indicate that the situations in which indium bleomycin is most likely to provide clinically relevant information are the distinction between recurrent tumour and post-radiotherapy changes in the thorax and pelvis, the diagnosis of recurrent carcinoma within the pelvis, and the distinction between bony metastases from carcinoma of the prostate and Paget's disease. Further clinical trials are necessary to assess these situations.

Abdominal Neoplasms↗
PubMed1975

Review article-Bone scanning.

The discovery of a number of phosphate complexes labelled with 99-Tc-m that localize in bone has aroused wide-spread interest in bone scanning. The physiological properties of these and other clinically useful bone-seeking radiopharmaceuticals are compared, and their physical properties assessed in relation to the characteristics and limitations of avilable detector systems. A hypothesis is put forward to explain the behaviour of the technetium-labelled agents. It is concluded that although there are differences in biochemical behaviour between these agents, strontium and fluorine, all three may, under suitable conditions, give similar clinical information. The radiation dose received by the patients is least with the usual dose of 99-Tc-m and the blood clearance of the diphosphonate and pyrophosphate preparations is faster than that of strontium, although slower than fluorine. The psi-ray energy of technetium permits a much greater efficiency of detection than of fluorine. These factors, toghether with the general availability of 99-Tc-m and its relatively low cost make the technetium diphosphonate or pyrophosphate preparations the agents of choice for most skeletal radioisotope imaging. However, there are as yet insufficient follow-up studies to be able to assess the incidence of either false-negative or false-positive findings with these agents.

Adolescent↗
PubMed1975

A comparison of 111In with 52Fe and 99mTc-sulfur colloid for bone marrow scanning.

Under most circumstances 52Fe, 111In, and colloid show a similar distribution of marrow. The lesser uptake of 111In by liver and spleen may occasionally be of value in permitting visualization of that portion of the spinal marrow obscured by these organs in the colloid scan. However, in red cell aplasia, when there is dissociation between phagocytic and erythropoietic functions, scanning with 111In gives no information about erythropoietic tissue distribution. Therefore, indium cannot be used as an analog for iron in the study of the hematopoietic system.

Bone Marrow Diseases↗
PubMed1973

Fat embolism in sickle cell disease.

Fat embolism is a known complication of marrow infarction in patients with sickle cell disease (Hb S/S and Hb S/C) disease. It should be considered in sickle cell crisis when there is deterioration in respiratory function, a fall in arterial PO(2), a normoblastaemia, and a thrombocytopenia in the peripheral blood. We now report a patient in whom the diagnosis was confirmed in life by identifying fat in the sputum, demonstrating disseminated intravascular coagulation, and using a double isotope technique to distinguish recent from old marrow infarction. Use of these features enabled an early diagnosis to be made which led to a successful outcome in a potentially fatal condition.

Adult↗